Soluble ligand CD40 and uric acid as markers of atheromatosis in patients with obstructive sleep apnea

Advances in Experimental Medicine and Biology

Volumn 839, Issue , 2015, Pages 55-60

  Kosacka, M ^a   Brzecka, A ^a   Piesiak, P ^a   Korzeniewska, A ^a   Jankowska, R ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Atherosclerosis; CRP; SCD40L; Sleep apnea syndrome; Uric acid

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; URIC ACID;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; ATHEROMATOSIS; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OXYGEN DESATURATION; OXYGEN SATURATION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SLEEP DISORDERED BREATHING; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; ATHEROSCLEROSIS; BLOOD; CASE CONTROL STUDY; COMPLICATION; MIDDLE AGED; MYOCARDIAL ISCHEMIA; SLEEP APNEA, OBSTRUCTIVE;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD40 LIGAND; FEMALE; HUMANS; HYPERTENSION; HYPERURICEMIA; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; SLEEP APNEA, OBSTRUCTIVE; URIC ACID;

EID: 84925024400     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/5584_2014_44     Document Type: Article

References (25)

1. Akinnusi ME, Paasch LL, Szarpa KR, Wallace PK, El Solh AA (2009) Impact of nasal continuous positive airway pressure therapy on markers of platelet activation in patients with obstructive sleep apnea. Respiration 77:25-31
2. Alderman M, Aiver KJ (2004) Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 20:369-379
3. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C (2009) The CD40/ CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54:669-677
4. Barcelo A, de la Pena M, Ayllon O, Vega-Agapito MV, Pierola J, Perez G, Gonzalez C, Alonso A, Agusti AG (2009) Increased plasma levels of asymmetric dimethylarginine and soluble CD40 ligand in patients with sleep apnea. Respiration 77:85-90
5. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE (2005) CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 25:2428-2434
6. Chakrabarti S, Rizvi M, Pathak D, Kirber MT, Freedman JE (2009) Hypoxia influences CD40-CD40L mediated inflammation in endothelial and monocytic cells. Immunol Lett 122:170-184
7. Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, Tugrul A (2007) The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 119:79-84
8. Hirotsu C, Tufik S, Guindalini C, Mazzotti DR, Bittencourt LR, Andersen ML (2013) Association between uric acid levels and obstructive sleep apnea syndrome in a large epidemiological sample. PLoS One 8:e66891
9. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ (2013) The role of uric acid in the pathogenesis of human cardiovascular disease. Heart 99:759-766
10. Kobayashi K, Nishimura Y, Shimada T, Yoshimura S, Funada Y, Satouchi M, Yokoyama M (2006) Effect of continuous positive airway pressure on soluble CD40 ligand in patients with obstructive sleep apnea syndrome. Chest 129:632-637
11. Lavie L, Lavie P (2009) Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J 33:1467-1484
12. Lutgens E, Daemen MJ (2002) CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 12:27-32
13. Lutgens E, Lievens D, Beckers L, Donners M, Daemen M (2007) CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 17:118-123
14. Mavroudi I, Papadaki HA (2011) The role of CD40/CD40 ligand interactions in bone marrow granulopoiesis. Scientific World J 11:2011-2019
15. McNicholas WT, Bonsigore MR (2007) Sleep apnea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 29:156-178
16. Mentzer RM, Rubio R, Berne RM (1975) Release of adenosine by hypoxic canine lung tissue and its possible role in pulmonary circulation. Am J Physiol 229:1625-1631
17. Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Oda N, Tanaka A, Yamamoto M, Ohta S, ODonnell CP, Adachi M (2007) Silent brain infarction and platelet activation in obstructive sleep apnea. Am J Respir Crit Care Med 175:612-617
18. Plywaczewski R, Bednarek M, Jonczak L, Gorecka D, Sliwinski P (2005) Hyperuricaemia in males with obstructive sleep apnea (OSA). Pneumonol Alergol Pol 73:254-259
19. Ridker PM (2003) Clinical application of c reactive protein for cardiovascular disease detection and prevention. Circulation 107:363-369
20. Rizvi M, Pathak D, Freedman JE, Chakrabarti S (2008) CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med 14:530-538
21. Ruiz Garcia A, Sanchez Armengol A, Luque Crespo E, Garcia Aguilar D, Romero Falcon A, Carmona Bernal C, Capote F (2006) Blood uric acid levels in patients with sleep-disordered breathing. Arch Bronconeumol 42:492-500
22. Schachter M (2005) Uric acid and hypertension. Curr Pharm Des 11:4139-4143
23. Seijkens T, Kusters P, Engel D, Lutgens E (2013) CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications. Diab Vasc Dis Res 10:115-122
24. Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Sisman AR, Yuksel F, Yesil S (2010a) The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. Clin Med Res 8:89-95
25. Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Yuksel F, Sisman AR, Yesil S (2010b) Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. Metabolism 59:305-313